Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT06414226 |
| Other study ID # |
2021/05-35 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
March 21, 2022 |
| Est. completion date |
October 24, 2022 |
Study information
| Verified date |
May 2024 |
| Source |
Firat University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
The Omega-3 polyunsaturated fatty acids (n-3 PUFA), associated with fish oil, has been one of
the most studied non-pharmacological subjects for its effect on Major Depression Disorder
(MDD). However, studies comparing the effect of krill oil, on depression are limited, that
has similar content and different structural forms with fish oil. This study was conducted to
evaluate the effectiveness of the use of krill and fish oil on clinical effects, biochemical
outcomes and eating behavior in individuals diagnosed with MDD. It was included 57 adult
individuals diagnosed with MDD in the psychiatry clinic in this study. Randomization was
performed after inclusion and exclusion criteria were applied in the study, and participants
were included in one of three groups. These groups are; 1) krill oil ((n=17),
(Eicosapentaenoic acid (EPA)=340 mg, Docosahexaenoic acid (DHA)=180 mg)), 2) fish oil
((n=17)), (EPA=360 mg, DHA=240 mg), 3) placebo ( (n=16), (EPA=0 mg, DHA=0 mg)). The duration
of the intervention was 8 weeks. Anthropometric measurements, biochemical outcomes and food
consumption records of the participants were taken at the beginning and end of the
intervention, and Hamilton depression rating scale (HDRS), depression anxiety stress-21
(DASS-21) and food craving questionnaire (FCQ) was applied to the participants. Statistical
Package for Social Sciences (SPSS) and R studio software were used for statistical analysis
of the data.
Description:
Introduction
Major Depressive Disorder (MDD) affects approximately 6% of the adult population worldwide
each year and is the second greatest contributor to the burden of chronic disease. In the
treatment of MDD, both psychotherapy and psychopharmacology are effective. However,
approximately 30% of patients do not achieve definitive recovery even after several treatment
attempts. Major depressive disorder can affect an individual's life as a whole and is
difficult to treat due to its high rate of relapse, and it is often associated with anxiety
and cardiovascular diseases (CVD), which can threaten an individual's life. It is estimated
that major depression is responsible for 3% of the global burden of disease according to the
World Health Organization (WHO) report and that this rate may increase to 7% by 2030.
Therefore, alternatives to effective treatments and prevention strategies are urgently needed
due to this increasing trend.
Omega-3 polyunsaturated fatty acids (n-3 PUFAs), identified with fish oil, became one of the
most researched nutritional topics on the effects of major depressive disorder. Omega-3
polyunsaturated fatty acids are shown to be effective in cardiovascular disease (CVD)
prevention due to their anti-inflammatory and cardio-protective effects. It can potentially
share common mechanisms with CVD, considering factors such as increased production of
pro-inflammatory cytokines, endothelial dysfunction and increases in plasma homocysteine
levels, which play a role in the pathophysiology of some psychiatric disorders such as
depression. It is possible that omega-3 has multiple positive effects on depression through
its neurogenesis and neuroplasticity abilities, as well as having a positive effect on
pathophysiological mechanisms. Appleton et al. conducted a Cochrane review to investigate the
effect of n-3 PUFA supplements on depression in adults. This review included 25 studies
(total 1438 participants) investigating the effect of n-3 PUFA supplements versus placebo and
1 study (40 participants) comparing n-3 PUFA supplements with antidepressant treatment. As a
result, it was reported that n-3 PUFA supplements had a modestly positive effect on
depression compared to placebo. However, it was emphasized in this report that the majority
of the studies (22 studies) had a low level of evidence. This was attributed to factors such
as high levels of bias, duration of follow-up, methodological errors and deficiencies due to
blinded designs. The general conclusion of the authors was that there was a need for high
quality intervention studies in this field.
Although there are a large number of studies focusing on the use of fish oil in depression,
research using krill oil, another source rich in n-3 PUFAs, is very limited. Krill oil is an
important shellfish that lives in the oceans around the Antarctic continent and attracts
attention in research due to its rich omega-3 fatty acid content. As krill is a species
living in cold regions, they are rich in EPA and DHA content, along with PUFAs in the form of
phospholipids and especially phosphatidylcholine in cell membrane structures. The form
containing and binding Docosahexaenoic acid (DHA) and Eicosapentaenoic acid (EPA) in krill
oil is phospholipids, contrary to triglyceride in fish oil. Therefore, the absorption and
bioavailability activities are different because of the difference in the forms in fish and
krill oil. Although there are studies on the effects of krill oil on the nervous system on
the human research, there is limited research on the effectiveness of krill oil on
depression. To our knowledge, there was only one pilot study on rats comparing the treatment
efficacy of fish and krill oil on depression. This study compared the antidepressant effects
of krill (EPA: 60 mg/500 mg, DHA: 35 mg/500 mg) and fish oil (EPA: 90 mg/500 mg, DHA: 60
mg/500 mg), vitamin B12 and imipramine. As a result, krill oil showed favorable results on a
number of variables compared to fish oil, but similar results were found in both groups. It
is important to compare the efficacy of krill and fish oil with similar EPA and DHA content
on depression to clarify the question of which of these oils in different forms may be more
effective on the disease.
Major depressive disorders affect many mechanisms such as food intake, taste perception and
food selection. When clinical pictures related to the nutritional status of depressed
individuals are examined; changes in appetite, increased consumption of certain food groups
and related changes in body weight are frequently observed. In addition, antidepressant drugs
used may also affect food intake and weight control. Eating behavior is under the control of
complex neural mechanisms, especially serotonin. At the same time, food intake is also
effective in the control of serotonin release in serotonergic neurons. Serotonin, which has a
bidirectional relationship with eating behavior, is a neurotransmitter involved in the
physiopathology of many psychiatric disorders. The presence of a disorder in the serotonin
pathway may explain the development of both psychiatric disorders and obesity in the patient.
As a result, it was reported that eating behavior disorders, interest in unhealthy food
consumption and increased appetite in major depressives, as in some psychiatric disorders,
may lead to an increase in body weight in individuals during the illness or in progressive
processes. There are several studies examining the relationship between depression and
obesity. However, clinical studies to determine the factors leading to this condition are
limited. In addition, data collection on eating behavior, appetite and weight status is
neglected in most clinical interventions in patients with depression. Therefore, it is
important to investigate the efficacy of n-3 fatty acids on appetite and body composition as
well as eating behaviors that examine food cravings in depressed individuals.
Considering all of these opinions, this study aimed to determine the effectiveness of krill
and fish oil on clinical effects, biochemical findings and eating behavior in individuals
diagnosed with MDD and to compare the results with the control group.
METHODS
This study was designed with a randomized double-blind placebo-controlled. The study was
conducted in the Psychiatry Clinic of Adıyaman University Training and Research Hospital with
50 patients over the age of 18 diagnosed with MDD. The duration of the intervention for each
participant was 8 weeks. The included patients received fish oil or krill oil or placebo. The
study was conducted in accordance with good clinical guidelines and in accordance with the
Declaration of Helsinki. Ethical approval was also obtained from the Ethics Committee of
Fırat University.
Participants
The study was enrolled with 66 patients with MDD who were over 18 years of age and fulfilled
the inclusion criteria. Inclusion criteria were; 1) being diagnosed with major depression by
a psychiatrist in accordance with DSM V diagnostic criteria 2) not taking antidepressant
medication or being on antidepressant medication for the last 1 month without medication
change 3) signing the informed consent form. The exclusion criteria were as follows; 1) those
who used more than two antidepressants 2) substance users in the last 6 months 3) alcohol
dependence 4) suicidal ideation and suicidal tendencies (followed up by clinicians) 5)
presence of other psychiatric disorders such as comorbid psychosis, schizophrenia and bipolar
(excluding dysthymia and anxiety) 6) Presence of serious chronic diseases 7) pregnant or
lactating women 8) Medication users that may cause emotional symptoms (Escitoloprom/Lexopro
etc.) 9) food allergies 10) individuals at high risk of bleeding or those taking
anti-coagulant drugs such as warfarin 11) Consumers of 3 or more servings of fish per week
12) Using any nutritional supplement 13) Hypercholesterolemia or taking medication for
hypercholesterolemia 14) those who did not sign the informed consent form.
Sample Size and Randomization and Blinded
The sample size was determined based on the findings of a similar study, using the G* power
3.1.9.7 software program with an effect size of 0.224, 95% confidence interval, and a margin
of error of 0.05.
This study was a randomized controlled double-blind study design. The assignment of patients
to groups (randomization) was performed by a statistician who was not involved in the
research and was concealed from the patients. At the first stage, stratified randomization
was performed to ensure homogeneous distribution of patients according to age and gender, and
then simple randomization was performed from each layer to ensure equal assignment to all
groups. Each patient was assigned a number between 1-60 and then stratified according to
gender (male and female) and age group (18-34 and 35-64 years). In the last stage, numbers
were generated with the R studio statistical program to assign an equal number of patients to
each group.
The statistician randomly assigned the color codes on the capsule bottles to each group and
each group received the test products from the researcher in a closed package according to
the color codes. These color codes were not known by the researchers and patients until the
endpoint of the study. In addition, the researcher, clinician, and participant were blinded
until the study was reported.
Intervention
The researcher conducted three 45-minute interviews with the participants for 8 weeks at the
beginning, mid and end of the study. In the first interview, patients were given the product
they should receive for 8 weeks in closed boxes.
Hamilton Depression Rating Scale in the questionnaire form was completed by the clinician to
assess the degree of depression and clinical status of the participants. Then, the remaining
parts of the questionnaire were directed to the patients. Anthropometric measurements were
performed after completion of the questionnaire. Blood samples were collected from
participants at the beginning and end of the study to analyze biochemical outcomes. The
second interview was conducted at mid-study at the end of week 4 and the final interview was
conducted at the end of week 8. In the second interview with the patients, the same
procedures were performed except for the collection of blood samples and the food craving
scale. In the last interview, the protocols were the same except for product administration.
Participants were prescribed a daily dose of 4 capsules (4×500 mg= 2 g/day) stored at the
appropriate temperature during the 8-week treatment period. Patients were informed to take 2
of the capsules in the daily oral bottle in the morning before breakfast and the other 2
capsules before dinner. The capsule bottles contained 500 mg concentrated krill oil, fish oil
or placebo capsules. The daily intake of EPA+DHA from krill and fish oil was determined as
520 mg and 600 mg, respectively.
Data Collection
Data of the participants were collected at the beginning, middle and end of the study, three
times in total, by face-to-face interview with a questionnaire form. The questionnaire
included sociodemographic characteristics, health information, lifestyle, Hamilton Depression
Rating Scale, Depression-Anxiety-Stress Scale, Food Cravings Scale, anthropometric
measurements and one-day food consumption record.
Statistical Analysis
Statistical Package for Social Sciences (SPSS) and R studio software program were used for
statistical analysis of the data. The mean and standard deviation values were given for
continuous data that met the normal distribution condition, otherwise the median and
quartiles (25th and 75th quartile values) were given. Categorical data were presented as
frequency and percentage. One-way ANOVA test was used to compare continuous variables that
met the normal distribution condition between the groups, and Kruskal-Wallis H test was used
for those that did not meet the normal distribution condition. Pearson chi-square test was
used to compare categorical data. Repeated measures ANOVA (General linear model) test was
used in the comparison of more than two dependent variables if they met the normal
distribution condition. To evaluate the differences between groups, p time, p group and p
group×time interaction effect were shown. The p time value expresses the comparison of any
numerical variable in the group between times. The p time×groups value expresses the
comparison of the numerical variable between the groups depending on time. In other words, it
gives information about whether the study groups have superiority over each other during the
intervention period on any variable. In addition, partial eta square values are presented for
the effect size of the interaction effect of group and time. A partial eta squared value of
<0.06 indicates a "small" effect size, a value between 0.06-0.14 indicates a "medium" effect
size and a value >0.14 indicates a "large" effect size. In addition, the standardized mean
differences, standard error, 95% confidence interval and p-values of the participants'
depression, anxiety and stress scores within each group were presented. Bonferroni correction
was used to calculate the p-value. If the normal distribution condition was not met, Friedman
test was used and if p<0.05, Wilcoxon test was performed in paired groups and Bonferroni
correction was used to calculate the p value. In addition, after the classification of
depression, anxiety and stress within the groups, the Stuart-Maxwell test (R studio) was used
to test the statistical significance of the changes in the severity of the disease before and
after the intervention. The results were evaluated at 95% confidence intervals and a pairwise
p<0.05 was considered statistically significant.
References
1. Bromet, E., et al., Cross-national epidemiology of DSM-IV major depressive episode. BMC
medicine, 2011. 9: p. 1-16.
2. Rush, A.J., et al., Acute and longer-term outcomes in depressed outpatients requiring
one or several treatment steps: a STAR* D report. Focus, 2008. 6(1): p. 128-142.
3. Thase, M.E., et al., Cognitive Therapy Versus Medication in Augmentation and Switch
Strategies as Second-Step Treatments: A STAR* D Report. Focus, 2008. 6(1): p. 104-119.
4. Organization, W.H., Depression. Fact sheet No. 369/October 2012. 2015.
5. Rangel-Huerta, O.D. and A. Gil, Omega 3 fatty acids in cardiovascular disease risk
factors: An updated systematic review of randomised clinical trials. Clinical nutrition,
2018. 37(1): p. 72-77.
6. Buoite Stella, A., et al., Update on the impact of omega 3 fatty acids on inflammation,
insulin resistance and sarcopenia: a review. International journal of molecular
sciences, 2018. 19(1): p. 218.
7. Crupi, R., A. Marino, and S. Cuzzocrea, n-3 fatty acids: role in neurogenesis and
neuroplasticity. Current medicinal chemistry, 2013. 20(24): p. 2953-2963.
8. Appleton, K.M., et al., Omega-3 fatty acids for depression in adults. Cochrane Database
of Systematic Reviews, 2021(11).
9. Burri, L., Krill oil supplementation and cognitive function, in Diet and Nutrition in
Dementia and Cognitive Decline. 2015, Elsevier. p. 1031-1038.
10. Colletti, A., et al., Advances in technologies for highly active omega-3 fatty acids
from krill oil: Clinical applications. Marine Drugs, 2021. 19(6): p. 306.
11. Adıgüzel, K.T., K. Işgın, and G. Pekcan, Krill yağı desteği ve yeni bilimsel kanıtlar.
Beslenme ve Diyet Dergisi, 2015. 43(3): p. 258-263.
12. Di Marzo, V., et al., Dietary krill oil increases docosahexaenoic acid and reduces
2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker
rats. International dairy journal, 2010. 20(4): p. 231-235.
13. Konagai, C., et al., Effects of krill oil containing n-3 polyunsaturated fatty acids in
phospholipid form on human brain function: a randomized controlled trial in healthy
elderly volunteers. Clinical interventions in aging, 2013: p. 1247-1257.
14. Zadeh-Ardabili, P.M., et al., Antidepressant-like effects of fish, krill oils and Vit
B12 against exposure to stress environment in mice models: current status and pilot
study. Scientific reports, 2019. 9(1): p. 19953.
15. Wurtman, R.J. and J.J. Wurtman, Brain serotonin, carbohydrate-craving, obesity and
depression. Obesity research, 1995. 3(S4): p. 477S-480S.
16. Paans, N.P., et al., Depression and eating styles are independently associated with
dietary intake. Appetite, 2019. 134: p. 103-110.
17. Lopresti, A.L., S.D. Hood, and P.D. Drummond, A review of lifestyle factors that
contribute to important pathways associated with major depression: diet, sleep and
exercise. Journal of affective disorders, 2013. 148(1): p. 12-27.
18. SM, S., Stahl'ın temel psikofarmakolojisi: nörobilimsel ve pratik uygulamalar. Cambridge
University Press. T Uzbay (çev. ed.), 2012. 3: p. 535-6.
19. Blaine, B., Does depression cause obesity? A meta-analysis of longitudinal studies of
depression and weight control. Journal of health psychology, 2008. 13(8): p. 1190-1197.
20. Luppino, F.S., et al., Overweight, obesity, and depression: a systematic review and
meta-analysis of longitudinal studies. Archives of general psychiatry, 2010. 67(3): p.
220-229.
21. Lespérance, F., et al., The efficacy of omega-3 supplementation for major depression: a
randomized controlled trial. Journal of Clinical Psychiatry, 2011. 72(8): p. 1054.
